India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers
The Strategic Shift For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing cohort of global Manufacturers, India is no longer purely an import destination. It is a manufacturing location, an export base, and increasingly, […]
Read MoreRegulatory Strategy for Recombinant Therapeutics and Monoclonal Antibodies in India
Recombinant Therapeutics and Monoclonal antibodies (mAbs) represent the fastest-growing and highest-value segment of the global Biological Medicines market. India’s mAb market is expanding rapidly, driven by biosimilar development, originator launches, and the government’s Ayushman Bharat health coverage expansion. For global biotech companies seeking Indian Regulatory approval for recombinant Therapeutics and […]
Read MoreUS FDA and EU GMP Expansion: Is Your Indian Manufacturing Site Ready for International Regulatory Scrutiny?
For Indian Pharmaceutical manufacturers with ambitions to supply regulated international markets – the United States, European Union, United Kingdom, Canada, and Australia — obtaining and maintaining approval from international regulatory authorities is both a strategic imperative and a sustained operational challenge. The gap between meeting Indian CDSCO GMP requirements and […]
Read More
Post-Market Surveillance Under Medical Device Rules, 2017
Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance (PMS). Under the Medical Device Rules, 2017, “Post-Marketing Surveillance” means a systematic process to collect and analyse information gained from […]
Read More
Post Approval Changes for Cosmetics in India: When Must You File, and What Are the Risks of Not Filing?
The Post-Market Compliance Gap Obtaining a COS-2 Import registration certificate or a COS-8 manufacturing license is not the end of the regulatory journey in India — it is the beginning of the post-market compliance phase. Any change to the product, its labelling, its formulation, or its manufacturing details after registration […]
Read More
EU MDR vs UK MHRA vs US FDA: What Global Medical Device Companies Should Prioritise First
For a Medical Device company that wants to expand globally, the biggest question arises is of market prioritization. Entering a market is both a regulatory challenge and a strategic decision. The three largest regulated Medical Device markets outside Asia are— the United States, the European Union, and the United Kingdom […]
Read MoreRegulation/Guidelines
How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework
One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions because the original data was not designed to serve multiple regulatory frameworks. Companies that plan their global market entry sequence intelligently can avoid […]
Regulation/Guidelines
Pharmacovigilance and Post-Marketing Compliance in India: The Expanding Obligation Every Pharmaceutical Company Must Understand
Drug approval is the beginning of a Pharmaceutical company’s regulatory obligation — not its culmination. Once a product receives marketing approval, an extensive and ongoing set of post-marketing requirements comes into effect: adverse event reporting, periodic safety update reports, post-marketing surveillance studies, label updates, and increasingly active signal detection and […]
Regulation/Guidelines
Top 7 Reasons Cosmetic Import Applications Get Delayed or Rejected by CDSCO — And How to Avoid Them
Introduction: Why Applications Stall CliniExperts has managed Cosmetic Import registrations across 30+ countries of origin and 350+ product types. In that experience, the majority of query and application delays are caused by a small, repeatable set of errors — errors that are entirely preventable with a structured pre-submission review. Reason […]